Company intelligence / Profile preview

Xoft

Nashua, New Hampshire, United Stateselekta.com ↗

Ownership: Private
Development stage: Other

Overview

The Xoft System is an FDA-cleared, CE-marked electronic brachytherapy platform that delivers targeted, isotope-free radiation directly to tumor sites. Clinical data support its safety and efficacy for early-stage breast cancer, gynecological cancers, and non-melanoma skin cancers. Studies report low morbidity, low local recurrence rates, and excellent cosmetic outcomes in treated patients

Therapeutic areas: Oncology
Modalities: DeviceRadiotherapy device (Electronic brachytherapy)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Xoft Axxent Electronic Brachytherapy System

Commercial

Indications: Breast cancer, Non-melanoma skin cancer, Gynecological cancers, Cervical cancer, Endometrial cancer, Colorectal cancer, Prostate cancer, Pancreatic cancer

Beyond the preview

Go deeper on Xoft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xoft.

Explore the full profile